Entity

Time filter

Source Type

BOYERTOWN, PA, United States

Herbal preparations are sold as dietary supplements in the United States and are subject to the rules and regulations of various health care and economic government agencies that monitor the sale of these products. One approach to assessing the usefulness of these substances is to focus on one particular disease state and then review both the primary literature and expert opinion. The common cold is an important illness due to its recurring nature, the number of people it afflicts, and its economic impact on patients. Dietary supplements have been shown to decrease the duration, the severity, and the frequency of symptoms of the common cold. The most commonly available supplements are zinc, ginseng, echinacea, and vitamin C. Data from expert opinion suggested that certain supplements are more beneficial than others to maintain ones health during episodes of the common cold. Expert opinion regarding the use of dietary supplements in other related infectious respiratory illnesses, such as the flu, when aggregated with expert opinion findings regarding the common cold were not contradictory. The primary literature provided insights into specific dosages and compounds that may be used in practice. © The Author(s) 2010. Source


Roberson J.A.,AWWA | Adams C.,Utah State University | Bench R.,Carollo Engineers | Rosen J.S.,Rockland, Inc.
Journal - American Water Works Association | Year: 2015

An independent set of recommendations for the Fourth Drinking Water Contaminant Candidate List (CCL4) was developed by prioritizing compounds with weightings based on data quality for occurrence and toxicity. This approach used key information including the number of studies used in the analysis and the associated spread and variability of the particular attributes between data sources, and resulted in four recommendation groups: • Group 1: Top priority for inclusion on CCL4â€"seven compounds plus one “super group†of disinfection by-products • Group 2: Include on CCL4 but insufficient information for a regulatory determination (need occurrence data)â€"11 compounds • Group 3: Could be included on CCL4 only if a future negative regulatory determination will be madeâ€"32 compounds • Group 4: No need to consider further in the CCL4 processâ€"55 compounds Having too many contaminants on the CCL results in a fragmented research agenda; conversely, some compounds might be missed on a CCL that is too small. © 2015 American Water Works Association. Source


Patent
Rockland, Inc. | Date: 2014-06-26

Recombinant


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 315.17K | Year: 2009

DESCRIPTION (provided by applicant): Lyme disease (LD) is caused by spirochetal bacteria from the genus Borrelia. Borrelia burgdorferi is the predominant cause of Lyme disease in the United States, whereas Borrelia afzelii and Borrelia garinii are implicated in most European cases. CDC reported 27,444 cases of Lyme disease in the United State in 2007 alone. It is estimated 2.5 million LD serological tests have been done annually. In response to the solicitation from NIAID in developing novel approaches for the diagnosis of Lyme disease, and to address the limitation of current LD assays, we propose to develop a highly sensitive Point-of-Care Multiplex Hand-Held Diagnostic Device capable of detecting the presence IgM and IgG antibodies against Borrelia species proteins in human serum, human saliva and human urine. The technology of our device is based on immunoprecipitation principles similar to those found in popular pregnancy tests. Lateral-flow chromatographic and flow-through tests offer fast detection of critical components for use in POC testing. The key feature of a proposed flow- through tests to achieve high sensitivity is the ability to covalently attach antibodies or antigens to highly intensely colored, nanometer-sized colloidal gold. Our lateral flow test assay development experience has demonstrated that the assay is as sensitive as ELISA, while reducing assay time from 8hrs to 5 minutes. Another key feature of the proposed test is the collection of 14 Borrelia specific in vivo-induced, non-denatured antigens that have been shown to elicit strong antibody response in humans. These antigens will be used to capture human Borrelia antibodies presented in human serum samples. In Phase I, we will use recombinant antigens of B. burgdorferi species, in Phase II, for each antigen we will use recombinant proteins from all three Borrelia species - B. burgdoferi, B. afzelii and B. garinii to further increase sensitivity. The POC assay will be inexpensive, less than 20 per test, robust, requires only a single step, field-capable, user-friendly, and temperature stable, with no requirement for sample processing. The results can be read in 10 to 30 minutes. PUBLIC HEALTH RELEVANCE: Lyme disease (LD) is the most widespread tick-borne disease affecting more than 27,000 people in the US in 2007 alone. The current LD diagnosis tests are both time consuming and expensive. We propose to develop a high accuracy Point-of-Care test similar to common pregnancy test. It is inexpensive, less than 20 per test, robust, requires only a single step, user-friendly, and temperature stable, with no requirement for sample processing. The results can be read in 10 to 30 minutes.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 225.00K | Year: 2014

DESCRIPTION (provided by applicant): Post-transcriptional RNA modification plays an important role in biological processes. For example, adenosines to nosiness or A-to-I editing are most abundant in the central nervous system (CNS) and essential for normalCNS development. Presently, the available reagents for detection, quantitation, or immunoprecipitation of modified RNA are extremely limited. Rockland Immunochemicals is collaborating with Aptagen to develop synthetic antibodies for detection and quantitation of modified RNAs. In Phase I, as a proof-of-principle, high-affinity and target-specific aptamers and aptamer-based detection assays for inosine and N6- methyladenosine containing RNA will be developed. In Phase II, aptamer reagents and assays to morethan 60 RNA modifications known in eukrayotes will be developed. These affinity reagents will be used in microarrays to profile RNA modifications in different mouse CNS disorder models. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:

Discover hidden collaborations